EP Patent

EP2771012A1 — New compounds

Assigned to GlaxoSmithKline Intellectual Property No 2 Ltd · Expires 2014-09-03 · 12y expired

What this patent protects

This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b - useful in the treatment of cancer and hyperproliferative diseases.

USPTO Abstract

This invention relates to heteroaryl compounds, containing a purinyl moiety, that inhibit DNA methyltransferase (DNMT) activity - including DNMT1, DNMT3a, or DNMT3b - useful in the treatment of cancer and hyperproliferative diseases.

Drugs covered by this patent

Patent Metadata

Patent number: EP2771012A1
Jurisdiction: EP
Classification: —
Expires: 2014-09-03
Drug substance claim: No
Drug product claim: No
Assignee: GlaxoSmithKline Intellectual Property No 2 Ltd
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.